Table 4.
Comparison of applied pharmacotherapy at the beginning of the follow-up period between the patients in the ESA-non-resistant group and ESA-resistant group.
| Therapy Taken | ESA-Non-Resistant Group (%) | ESA-Resistant Group (%) | p | |
|---|---|---|---|---|
| Anti-inflammatory drugs | Yes | 58.3 | 41.7 | 0.144 |
| No | 80.0 | 20.0 | ||
| Anti-phosphate agents | Yes | 71.4 | 28.6 | 0.375 |
| No | 81.8 | 18.2 | ||
| Beta-blockers | Yes | 65.6 | 34.4 | 0.051 |
| No | 88.0 | 12.0 | ||
| ACEIs/ARBs | Yes | 100.0 | 0.0 | 0.013 |
| No | 67.4 | 32.6 | ||
| Statins | Yes | 80.0 | 20.0 | 0.313 |
| No | 68.2 | 31.8 | ||
| Antithrombotic drugs | Yes | 64.3 | 35.7 | 0.297 |
| No | 79.1 | 20.9 | ||
| Iron supplementation | Yes | 60.0 | 40.0 | 0.059 |
| No | 83.8 | 16.2 | ||
| Folic acid supplementation | Yes | 79.3 | 20.7 | 0.490 |
| No | 71.4 | 28.6 | ||
| Vitamin B12 supplementation | Yes | 60.0 | 40.0 | 0.161 |
| No | 81.0 | 19.0 | ||
| Vitamin C supplementation | Yes | 78.6 | 21.4 | 0.589 |
| No | 72.4 | 27.6 | ||
| Vitamin D supplementation | Yes | 76.9 | 23.1 | 0.812 |
| No | 74.2 | 25.8 | ||
Legend: ESA—erythropoiesis-stimulating agents; ACEIs—angiotensin-converting enzyme inhibitors; ARBs—angiotensin II receptor blockers.